CN1919209A - Pharmaceutical composition for healing skin wound - Google Patents
Pharmaceutical composition for healing skin wound Download PDFInfo
- Publication number
- CN1919209A CN1919209A CN 200610052503 CN200610052503A CN1919209A CN 1919209 A CN1919209 A CN 1919209A CN 200610052503 CN200610052503 CN 200610052503 CN 200610052503 A CN200610052503 A CN 200610052503A CN 1919209 A CN1919209 A CN 1919209A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- skin wound
- healing skin
- weight portion
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010072170 Skin wound Diseases 0.000 title claims abstract description 18
- 230000035876 healing Effects 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 69
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 25
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 25
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 25
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 23
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 14
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940116229 borneol Drugs 0.000 claims abstract description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 24
- 208000027418 Wounds and injury Diseases 0.000 claims description 22
- XWTXZJITNNRDLC-UHFFFAOYSA-K bis[(2-hydroxyacetyl)oxy]alumanyl 2-hydroxyacetate Chemical compound [Al+3].OCC([O-])=O.OCC([O-])=O.OCC([O-])=O XWTXZJITNNRDLC-UHFFFAOYSA-K 0.000 claims description 19
- 125000001246 bromo group Chemical group Br* 0.000 claims description 13
- 229910000951 Aluminide Inorganic materials 0.000 claims description 8
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims description 8
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 claims description 8
- 229940104825 bismuth aluminate Drugs 0.000 claims description 8
- 229960003657 dexamethasone acetate Drugs 0.000 claims description 8
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 claims description 8
- -1 diol compound Chemical class 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 7
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 6
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 6
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 6
- PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 claims description 6
- 229960004584 methylprednisolone Drugs 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 229960005294 triamcinolone Drugs 0.000 claims description 6
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 5
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 5
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 5
- UJOHNXQDVUADCG-UHFFFAOYSA-L aluminum;magnesium;carbonate Chemical compound [Mg+2].[Al+3].[O-]C([O-])=O UJOHNXQDVUADCG-UHFFFAOYSA-L 0.000 claims description 5
- 229960002537 betamethasone Drugs 0.000 claims description 5
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- 229960004544 cortisone Drugs 0.000 claims description 5
- 229960002011 fludrocortisone Drugs 0.000 claims description 5
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims description 5
- 210000004877 mucosa Anatomy 0.000 claims description 5
- 229960005205 prednisolone Drugs 0.000 claims description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229960002233 benzalkonium bromide Drugs 0.000 abstract description 6
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 abstract description 6
- 239000000470 constituent Substances 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 2
- 239000011505 plaster Substances 0.000 abstract description 2
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 235000013772 propylene glycol Nutrition 0.000 abstract 1
- 229960002668 sodium chloride Drugs 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 27
- 239000007788 liquid Substances 0.000 description 22
- 239000000499 gel Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000017 hydrogel Substances 0.000 description 12
- 208000014674 injury Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 231100000241 scar Toxicity 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000000589 cicatrix Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 6
- 229940043276 diisopropanolamine Drugs 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 239000000645 desinfectant Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000005030 aluminium foil Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 208000009084 Cold Injury Diseases 0.000 description 3
- 206010051814 Eschar Diseases 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003518 caustics Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002595 cold damage Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 231100000333 eschar Toxicity 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000003677 hemocyte Anatomy 0.000 description 3
- 229940000351 hemocyte Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 208000018380 Chemical injury Diseases 0.000 description 2
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 2
- 229960000199 bismuth subgallate Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- JTZPPHUZZDKEOC-RBQAPOGLSA-A chembl2367706 Chemical compound O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 JTZPPHUZZDKEOC-RBQAPOGLSA-A 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Natural products C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000003656 Electric Burns Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a pharmaceutical composition for healing skin wounds, which comprises the constituents of aluminium acetate basic, propylene glycol, glycerin, hydroxyethyl cellulose, synthetic borneol, sodium chloride, hydrocortisone and benzalkonium bromide. The composition can be made into dose forms of cream, paste, bandage and plaster.
Description
Technical field
The present invention relates to pharmaceutical composition, particularly a kind of various burns that are used to heal, scald, burn, the local medicine composition of skin wound such as knife injury, sunburn, cold injury and chemical reagent caustic trauma.
Background technology
Skin is the outermost protective tissue of human body, is the main barrier of human body contact external environment.Because human wearing during evolution, human skin has become tender and lovely, very easily is subjected to physical property in the environment, mechanicalness (as, knife injury, the incised wound etc. of shaving), and the injury of chemical.Because and the microbe species of human coexistence is various, the natural cover for defense of resisting microorganism invasion as human body when skin is during because of injured going to pot, just be vulnerable to the microorganism invasion, and downright bad skin histology is the best " culture medium " of growth of microorganism breeding, and burn wound is very easily infected.Therefore, the human skin wound that is I guess the slightest as long as deal with improperly, is infected by it just may, even involve whole body.
Burn refers generally to the traumatic sufferer because of caused by heat-flash material infringement human bodies such as flame, boiling water, lime water.The traumatogenic reason of burn is a lot, and according to the burn patient statistics of being in hospital, modal is heat injury, accounts for 90%, and as boiling water, flame, rolls burns such as oil, hot medicated porridge, steam at thermometal; Secondly be chemical burn,, account for 7% as strong acid, strong alkali, phosphorus, magnesium etc.; Be electric burn once more, account for 4%; Other also has radiation burn, flash burn etc.Scald and flame burn wherein in life account for 84%.The weight of burn depends on burn surface area, the degree of depth and privileged sites burn situation.
So far, relevant external is protected the vulnerary thing and is protected and hinder apparatus (as patch, binder etc.) early for people are familiar with, and is extensive use of (for example using povidone-iodine, silver sulfadiazine, hydrocortisone, neomycin, Borneolum Syntheticum and all Chinese herbal medicine).So far, thousand pieces nearby of the relevant patents of domestic bulletin only.With regard to protecting with regard to the vulnerary component of being announced in this class patent, majority belongs to the Chinese herbal medicine class, as Chinese patent application number: 0410092761; 0410086762; 0410066115; 0410045080; 0410024408; 0410026242; 0410045418; 0410022541; 0410012954; 0410022161; 0410010728; 0410023641 or the like.Other belong to the Western medicine class, as Chinese patent application number: 0410000679; 0410025977; 0410010870; 96109050 or the like.Also have some belong in, the Western medicine composite class, as Chinese patent application number: 0410050930; 99100719; 0410014695; 0410010195 etc.These components respectively have pluses and minuses.For example the Chinese herbal medicine class takes effect slowly usually, and finished product is sepia mostly, easily makes dye; Though the Western medicine class takes effect comparatively fast, some crowd takes place such as side reactions such as allergy, pimple, prurituss in regular meeting.Importantly, consult all relevant domestic patents, do not see that the milky exterior-applied liquid medicine gel-like that is combined by aluminum hydroxyacetate, propylene glycol and hydroxyethyl-cellulose just like main constituent of the present invention is protected and hinder dressing.
In fact, Australian Patent (Australian patent No.558482) was just once announced the patent of invention that colourless hydrogel with propylene glycol and hydroxyethyl-cellulose composition can effectively heal a wound, stop external such as bacterial infection to protect skin ulcer dressing.Unfortunately this combination is failed deep consideration to the prevention problem of side reactions such as the incrustation that occurs in the Wound healing and bone regeneration or granuloma, and cause some skin traumas, burn or burn etc. the patient pachylosis can occur or stay cicatrix or the scene of projection on skin behind the wound healing.Scar hyperplasia is a serious sequela behind the burn patient wound healing, due to the pathological change in the agglutination of wound surface own.According to statistics, among the wounded of scar hyperplasia, the age is accounting for 70-80% below 30 years old; Coloured race and the crowd that cicatrix body constitution is arranged have the tendency that the cicatrix hyperplasia takes place; Chemical burn, napalm burn often produce serious cicatrix; Burn dark more (the dark above wound surface of II degree), scar hyperplasia is obvious more; Traumatic infection regular meeting increases the chance and the order of severity of cicatrization; Scar contracture and hypertrophy can have a strong impact on patient's quality of life.Obviously, this class side reaction will make the patient regret all the life if occur in exposure portion such as head, face and hands.
By TaiWan, China Youhe Biochemical Science ﹠ Technology Co., Ltd., Chen Junting and protecting of Chen Junbin invention are hindered component, have successively applied for Chinese patent (99100719) and United States Patent (USP) (US Patent No.6232341).It protects hinders component and is made up of basic bismuth gallate, P-aminobenzene-sulfonamide, boric acid, Borneolum Syntheticum and vaseline.These product have healing a wound simultaneously and stop the more function of back cicatrix generation.Significant be, this is invented by U.S. HedonistBiochemical Technologies (U.S.A.), Inc., Plono, Texas 75075, USA produces in enormous quantities, trade name SuileTM Wound Dressing.Entering Chinese market at present.Unfortunately, it is ginger-colored that these product are, unsuitable to the Chinese colour of skin; These product do not belong to gel-like, and easily dehydration becomes dry; Main constituent is a bismuth subgallate, costs an arm and a leg, and does not domesticly see production so far.Cause this dressing to be coated in Aluminium Foil Package load on 10 * 10cm liner, every price is up to 100 yuans.
Summary of the invention
The objective of the invention is to overcome the deficiency of prior art, provide and the object of the present invention is to provide a kind of various burns that are used to heal, scald, burn, the local medicine composition of skin wounds such as knife injury, sunburn, cold injury and chemical reagent caustic trauma, it can integrate hemostasis, antiinflammatory, go non-ly to give birth to tissue (as eschar, cicatrix etc.) and antibiotic etc. multi-functional protecting hindered dressing.
The inventor tests discovery, adds aluminum hydroxyacetate and can make the effect of treatment wound strengthen the accelerated in wounds rehabilitation greatly in this propylene glycol and hydroxyethyl-cellulose combination.The more important thing is that aluminum hydroxyacetate can also suppress or prevent the formation of proliferative scar tissue.If again and glucocorticoids (as hydrocortisone, dexamethasone acetate etc.) combine then this inhibition or prevent that the effect that the proliferative scar tissue forms from then can further strengthen.
The present invention solves the problems of the technologies described above the technical scheme that is adopted:
A kind of pharmaceutical composition that is used for healing skin wound is characterized in that component is as follows:
Aluminum hydroxyacetate 0.5～10 weight portion,
Propylene glycol 15～25 weight portions,
Glycerol 15-25 weight portion,
Hydroxyethyl-cellulose 1～4 weight portion,
Synthetic borneol 0.5～3 weight portion,
Sodium chloride 0.7～1.2 weight portion,
Hydrocortisone 0.2～1 weight portion,
Bromo geramine 0.05～0.2 weight portion.
The technical scheme that the present invention can also adopt is:
Also available other of aluminum hydroxyacetate contains aluminide and replaces, and comprises bismuth aluminate, Dihydroxyaluminum Aminoacetate, Basic Magnesium Aluminum Carbonate;
Propylene glycol also can be replaced by three pharmaceutically acceptable diol compound and derivants thereof more than the carbon atom, as butanediol;
Hydroxyethyl-cellulose can be replaced by the cellulose derivative of other high pressure resistant sterilization;
Hydrocortisone also can be replaced by other glucocorticoids that is used for the treatment of anaphylaxis dermatosis, dermatitis, eczema, skin and mucosa pruritus clinically, as dexamethasone acetate, cortisone, fludrocortisone, prednisone, triamcinolone, fluocinolone acetonide, betamethasone, methylprednisolone, prednisolone;
Bromo geramine also can be replaced by non-harmful antiseptic, as hibitane;
The combination of aluminum hydroxyacetate and hydrocortisone can contain the combination replacement that aluminide comprises bismuth aluminate, Dihydroxyaluminum Aminoacetate, Basic Magnesium Aluminum Carbonate and other glucocorticoids such as dexamethasone acetate, cortisone, fludrocortisone, prednisone, triamcinolone, fluocinolone acetonide, betamethasone, methylprednisolone, prednisolone by other;
Aluminum hydroxyacetate: propylene glycol: the ratio of hydroxyethyl-cellulose combination is 1: 12.5: 1;
Its viscosity can be adjusted by the dosage of hydroxyethyl-cellulose and aluminum hydroxyacetate, thereby compositions is deployed into paste, pasty state, frost, emulsion dosage form;
Can coat solid support surface or wherein, for example gauze, sthptic sponge, be combined into protect hinder gauze, protect hinder paste, protect hinder cotton, protect and hinder band, protect and hinder sponge, Wound protective film.
Because the present invention has taked above-mentioned technical measures, it compared with prior art has following advantage:
Be a kind ofly to integrate hemostasis, antiinflammatory, go non-ly to give birth to tissue (as eschar, cicatrix etc.) and antibiotic etc. multi-functional the protecting of milky hindered dressing.This dressing can stand autoclaving to be handled, its viscosity can be allocated arbitrarily again, and therefore can be made into the burn that is applicable to various sizes and form, scald, burn, the local wound of skin wounds such as knife injury, sunburn, cold injury and chemical reagent caustic trauma protects and hinders with frost, cream, binder, applies ointment or plaster etc.
Protect in the present invention and to hinder in the dressing combination, each component function and effective range by weight are respectively described below:
Aluminum hydroxyacetate:
The world of medicine knows that for a long time many aluminides are very powerful in the treatment gastrointestinal disease.For example; sucralfate has another name called ulcerlmin; formal name used at school sucrose sulfuric ester alkaline aluminium salt, its energy and pepsin complexation, directly Profilin degrading activity; form a kind of protecting film; gastric mucosa there are stronger protective effect and antacid effect, help mucosa regeneration, promote ulcer healing; toxicity is low, is a kind of good gastrointestinal ulceration therapeutic agent.It is as dihydroxyaluminum aminoacetate (Dihydroxyaluminum Aminoacetate), Basic Magnesium Aluminum Carbonate, compound bismuth aluminate tablets (bismuth aluminate compound), and all contain gastropine control the gastropathy medicine.Comprise gastropine, RUDD-U stomach tablets, walugel tablet, the plain recovering capsule of stomach, caved-S tablets etc.Mostly indicate on their description and mainly be applicable to gastric and duodenal ulcers, chronic superficial gastritis, duodenal bulbar inflammation, hyperchlorhydria and nervous dyspepsia, have effects such as antiacid, sorption, local hemostasis, protection ulcer surface.This shows that aluminide is extensive use of in the world of medicine already, the effect of its institute's tool local hemostasis, protection ulcer surface in gastrointestinal also is that the world of medicine is confessed.Curiously, the finding aluminide is peroral dosage form so far, does not see to be used for wound.The inventor experiment showed, that many aluminides are used to protect wound outward and also have hemostasis, protect effects such as hindering face.The preferred aluminum hydroxyacetate of the inventor is to find that it not only can accelerating wound healing, can also suppress or prevent the formation of proliferative scar tissue.Effective range is preferably 1～4 weight portion between 0.5～10%; 1.5～2.5 weight portions more preferably.
Propylene glycol:
Effect that single combination that is made of propylene glycol/hydroxyethyl-cellulose just can effectively heal a wound, stop external such as bacterial infection to protect skin ulcer dressing has been proved by Australian Patent (Australian patent No.558482).Propylene glycol also can by pharmaceutically acceptable three more than the carbon atom diol compound and derivant thereof replaced, as butanediol etc.The present invention proves that the propylene glycol effective range is between 15～30 weight portions, and during greater than 30 weight portions, some patient can feel pain; Curative effect obviously descends during less than 15 weight portions.So be preferably 20～28 weight portions, more preferably 22～26 weight portions.
Hydroxyethyl-cellulose
Be the main constituent that forms hydrogel, the ability autoclaving.Hydroxyethyl-cellulose can be replaced by the cellulose derivative of other high pressure resistant sterilization.Effective range does not influence it and protects and hinder effect between 1～4 weight portion in this scope.But, the inventor find the hydrogel class protect hinder series than non-gel-like protect hinder on the effect more useful.Because, not only can preserve moisture, more promote wound healing because of promoting effective ingredient to infiltrate the non-tissue of giving birth to by the jelly that hydrogel forms.Through looking into Chinese patent, also there is the low amounts of water gel-like to protect and hinders patent announcement.For example, application number is that 200410010870 the described hydrogel of patent is made up of chemical paste (CMC-2Na); 200410010849 patent is then used polyvinyl alcohol (PVA); 03150654 patent is more used aqueous emulsion of polyurethane/PVP/PVA to make up to modulate the hydrogel class to protect to hinder goods, and aluminum hydroxyacetate/propylene glycol/hydroxyethyl-cellulose combination allotment hydrogel protects the Chinese patent of hindering dressing still not to be had and adopt as the present invention.The inventor finds that this dressing viscosity will strengthen because of the dosage of hydroxyethyl-cellulose and aluminum hydroxyacetate.The adjustment of viscosity whereby can be deployed into this dressing paste, pasty state, frost, Emulsion etc.For this reason, the contained hydroxyethyl-cellulose of this dressing is preferably 1～2 weight portion.
The effective range of the ratio of propylene glycol/hydroxyethyl-cellulose combination is 12.5: 1.
Synthetic borneol:
Borneolum Syntheticum has another name called Borneolum Syntheticum.Chemistry camphol by name, its chemical structural formula as shown in the figure.Medicinal Borneolum Syntheticum is synthetic with chemical method, so name synthetic borneol (BorneolumSyntheticum).It has special fragrance, has alleviating pain and detumescence, an effect of the refreshment of having one's ideas straightened out, and is usually used in the calentura coma, convulsion is fainted, the apoplexy syncope due to accumulation of phlegm, and stagnation of QI sudden syncope, the attacked by pestiferous factors stupor, conjunctival congestion, aphtha, laryngopharynx swelling and pain, auditory meatus is suppurated.Be many protect one of the composition of hindering dressing (seeing above-listed Chinese patent for details).Because of it is almost insoluble in water, and the propylene glycol coupling then can strengthen percutaneous rate, see document for details: the Cheng Yi of Traditional Chinese Medicine University Of Guangzhou etc. and Jiangxi Chinese medicine institute Yu Jin protect etc., " dynamic characteristic of Borneolum Syntheticum percutaneous rate in the different solvents carrier ", Chinese herbal medicine phase the 31st volume pharmacological evaluation and clinical observation in 2000 the 8th.This article has compared Borneolum Syntheticum at 50% propylene glycol, and 24h sees through the dynamics of rat skin in vitro in the single-phase and heterogeneous solvent carrier of 5% linoleic acid and 5% azone.The percutaneous rate of the Borneolum Syntheticum of result in 50% propylene glycol will improve 3.89～6 times than other carrier respectively; 55 times have been improved than the normal saline contrast.Remove this, the inventor finds again, added synthetic borneol in this combination after, can change into the milky hydrogel by colourless hydrogel.Of the present invention protecting hinders that contained synthetic borneol effective range is 0.5～3 weight portion in the dressing, is preferably 1～2.5 weight portion, more preferably 1.5～2 weight portions.
Sodium chloride:
In nature and daily life, phenomenon of osmosis is extensively to exist.All contain the sodium chloride composition in the blood of human body.Under normal circumstances, intracellular solution must be kept finite concentration with extracellular blood plasma.The people enters the normal saline of blood plasma in when transfusion, also must keep certain concentration, and promptly 0.9%.If joined the concentration of normal saline rare or misused distilled water, so, the concentration of transfusion back blood plasma will inevitably be thinning.Like this, the moisture in the blood plasma will permeate in the big hemocyte of concentration.The result will cause that hemocyte expands, or even breaks, and haemolysis takes place.If the normal saline overrich that is input into, so, the concentration of transfusion back blood plasma will increase, and the moisture in the hemocyte can cause cell dehydration to exosmosis again.Therefore, the normal saline of transfusion usefulness should have strict concentration.In daily life, people use strong brine sauerkraut, butcher's meat always, and purpose is sterilizing, just allow antibacterial outwards seep water and be killed.The inventor has added sodium chloride according to this principle in component, to form the purpose that tool sterilizes than hyperosmosis.In view of the existence of other component of the present invention, the sodium chloride effective range that forms hyperosmosis is 0.7～1.2 weight portion, is preferably 0.8～1.0 weight portion, more preferably 0.9 weight portion.
Hydrocortisone:
The inventor finds glucocorticoids, as hydrocortisone, dexamethasone acetate, cortisone, fludrocortisone, prednisone, triamcinolone (omcilon), fluocinolone acetonide, betamethasone, methylprednisolone, prednisolone or the like, not only have antiinflammatory and control skin allergy that the world of medicine is known, clinical being used for the treatment of outside the diseases such as anaphylaxis dermatosis, dermatitis, eczema, skin and mucosa pruritus, the inventor finds that also they can suppress or prevent the formation of proliferative scar tissue (as eschar etc.).Wherein especially with dexamethasone acetate and hydrocortisone best results.One of inventor once tried out the elimination of and the back of the hand portion old black speck facial in self, and it is black to prove that they can make old black speck move back earlier, calmed down protruding spot again, reached the degree that almost is difficult to self colour of skin resolution at last.Therefore added glucocorticoids in the component of the present invention.Wherein, preferred hydrocortisone (Hydrocortisone; Claim cortisol, hydrocortisone again), effective range is 0.2～1.5 weight portion, is preferably 0.5～1,2 weight portions, more preferably 0.8～1.0 weight portion.
Bromo geramine:
From the above-listed relevant Chinese patent of having announced of hindering dressing that protects, suffer infected by microbes in order to prevent wound, in component, add antiseptic usually.As everyone knows, antiseptic is of a great variety, really can choose wantonly.Puzzling is not see so far to adopt as bromo geramine of the present invention to be used as protecting the patent report of hindering antiseptic in the dressing.Bromo geramine claims again: benzalkonium bromide (benzalkonium bromide), Benzalkonium Bromide, benzalkonium bromide, Benzalkonium Bromide.Chemistry full name dodecyl dimethyl benzyl amine bromide by name.Bromo geramine is a kind of wide-spectrum bactericide, and sterilizing power is strong, to skin and organize nonirritant, metal, rubber is not had corrosiveness.Medical profession is widely used in the sterilization of hands, skin, mucosa, apparatus etc. already.The more important thing is, (the enforcement time: October 1 calendar year 2001) stipulate in the 7th disinfecting: " that should select is safer to people, milch cow and environment, do not have residual toxicity, and equipment not have to destroy and should not produce harmful disinfectant that accumulates in the cattle body by disinfectant in " the pollution-free food raising dairy cattle management guideline " of calendar year 2001 JIUYUE 3 days issue for the Ministry of Agriculture of country.Available disinfectant has: carbolic acid (phenol), paracresylol, bisphenols, hypochlorite, organic iodine mixture (iodophors), peracetic acid, quicklime, sodium hydroxide (Caustic soda), potassium permanganate, copper sulfate, bromo geramine, Oleum Pini, ethanol and lysol etc. ".One-level to SARS patient in " the new guideline of hospital's SARS infection control (in full) (4) " that on May 6th, 2003, Ministry of Public Health was announced is protected 3 sections of regulations of Xiang Zhongdi: " medical worker carries out hands cleaning and sterilization after contacting patient at every turn immediately.The hands sterilization was rubbed 1～3 minute with 0.3～0.5% disinfectant tamed iodine or quick hand disinfectant (hibitane alcohol, bromo geramine alcohol, 75% ethanol etc.) ".As from the foregoing, the present invention is preferred bromo geramine in numerous and diverse antiseptic, be it be national authority department conclusive evidence it be effective and non-harmful antiseptic.Its effective range is 0.05～2 weight portion, is preferably 0.08～0.17 weight portion, more preferably the 0.1--0.15 weight portion.
Of the present invention protecting hindered dressing and can be coated such as solid support surface such as gauze, sthptic sponges or wherein just can be combined into hemostatic gauze (CN95115433) described in Chinese patent; (CN0410033680) pasted in hemostasis; Styptic cotton (CN0410022462); Tourniquet (CN0420043971) sthptic sponge pressing plate (CN042002264) pressing belt (CN0420071997) dosage form (CN0410058134) or the like of filming.
The specific embodiment
Below the present invention is described in further detail.
Embodiment 1:
Preparation is protected and is hindered the hydrogel moist dressing
1. claim propylene glycol 150g, add glycerol 100g, water-bath is warmed to 70 ℃.Stir and to add synthetic borneol 0.5g down, electronic be stirred to molten entirely.Add hydroxyethyl-cellulose 1g again, continue to be stirred to molten entirely.
2. claim aluminum hydroxyacetate 0.5g, add above-mentioned solution and size mixing on a small quantity that make suring, it is agranular thin starchiness.This serosity is just joined in the above-mentioned 1. liquid under vigorous stirring lentamente, till continuing to be stirred to its homogeneous and disperseing.
3. get distilled water 600ml, add sodium chloride 0.7g, bromo geramine 0.05g stirs to make and joins in the above-mentioned 2. liquid after molten entirely.
4. above-mentioned milky 3. behind the liquid cool to room temperature, is added the 0.2g hydrocortisone, stir make molten entirely.
5. add distilled water to 1000ml, stir homogeneous and be finished product.
Embodiment 2:
Preparation is protected and is hindered the hydrogel moist dressing
1. claim butanediol 200g, add glycerol 200g, water-bath is warmed to 70 ℃.Stir and to add synthetic borneol 1.5g down, electronic be stirred to molten entirely.Add hydroxyethyl-cellulose 2g again, continue to be stirred to molten entirely.
2. claim bismuth aluminate 4.5g, add above-mentioned solution and size mixing on a small quantity that make suring, it is agranular thin starchiness.This serosity is just joined in the above-mentioned 1. liquid under vigorous stirring lentamente, till continuing to be stirred to its homogeneous and disperseing.
3. get distilled water 600ml, add sodium chloride 0.9g, hibitane 0.1g stirs to make and joins in the above-mentioned 2. liquid after molten entirely.
4. above-mentioned milky 3. behind the liquid cool to room temperature, is added the 0.6g dexamethasone acetate, stir make molten entirely.
5. add distilled water to 1000ml, stir homogeneous and be finished product.
Embodiment 3:
Preparation is protected and is hindered the hydrogel moist dressing
1. claim propylene glycol 250g, add glycerol 250g, water-bath is warmed to 70 ℃.Stir and to add synthetic borneol 3g down, electronic be stirred to molten entirely.Add hydroxyethyl-cellulose 4g again, continue to be stirred to molten entirely.
2. claim Dihydroxyaluminum Aminoacetate 10g, add above-mentioned solution and size mixing on a small quantity that make suring, it is agranular thin starchiness.This serosity is just joined in the above-mentioned 1. liquid under vigorous stirring lentamente, till continuing to be stirred to its homogeneous and disperseing.
3. get distilled water 600ml, add sodium chloride 1.3g, bromo geramine 0.2g stirs to make and joins in the above-mentioned 2. liquid after molten entirely.
4. above-mentioned milky 3. behind the liquid cool to room temperature, is added the 0.2g prednisone, stir make molten entirely.
5. add distilled water to 1000ml, stir homogeneous and be finished product.
Embodiment 4:
Preparation is protected and is hindered the subsides of three-dimensional grid gel dressing
1. claim propylene glycol 2500g, glycerol 1500g has used the dissolved 45g synthetic borneol of small amount of ethanol, and 25g trichlorine hydroxyl two stupid ethers stir under the room temperature and make homogeneous.
2. claim hydroxyethyl-cellulose 300g, poly propenoic acid sodium acrylate copolymer 300g, sodium polyacrylate 300g adds in the above-mentioned 1. liquid that is stirring successively, and it is molten entirely to make sure item by item.
3. measure distilled water 6000ml, add the 150g polyvinylpyrrolidone under the heated and stirred.Treat that it adds 135g sodium chloride after molten entirely again, the 150g diisopropanolamine (DIPA) stirs up to molten entirely.
4. measure distilled water 3000ml, add 300g aluminum hydroxyacetate and 100g triamcinolone, high speed electric joins in the above-mentioned 3. liquid that is stirring after stirring and making it be agranular thin starchiness down.
5. above-mentioned 2. liquid is poured into and pour into above-mentioned 4. liquid again after froth in vacuum becomes the glue machine, start the back about 10min of running and can become glue.
6. this is had three-dimensional grid gel structure thing and move in the film-forming machine, configure non-woven fabrics egative film and airtight synthetic plastic top flat width, and behind the mesophase gel layer thickness, can start film-forming machine, promptly get and open multi-functional protecting greatly and hinder the subsides of three-dimensional grid gel dressing.
7. an above-mentioned 6. big dressing paste of opening, put into ventilating kitchen layer lattice one by one.Start big air quantity, make gel dehydration aging, can lift easily and till when not being stained with gel up to the dressing paste teleblem.
8. above-mentioned 7. the big dressing paste of opening, to put into film cutting machine and be cut into behind the various sizes dressing paste aluminium foil bag of can vacuum packet packing into, this is that multi-functional protecting hindered the three-dimensional grid gel dressing and pasted finished product.
Embodiment 5:
Preparation is protected and is hindered the subsides of three-dimensional grid gel dressing
1. claim butanediol 1500g, glycerol 2500g has used the dissolved 15g synthetic borneol of small amount of ethanol, and the 25g trichloro hydroxyl diphenyl ether stirs under the room temperature and makes homogeneous.
2. claim hydroxyethyl-cellulose 100g, poly propenoic acid sodium acrylate copolymer 300g, sodium polyacrylate 300g adds in the above-mentioned 1. liquid that is stirring successively, and it is molten entirely to make sure item by item.
3. measure distilled water 6000ml, add the 150g polyvinylpyrrolidone under the heated and stirred.Treat that it adds 45g sodium chloride after molten entirely again, the 150g diisopropanolamine (DIPA) stirs up to molten entirely.
4. measure distilled water 3000ml, add 100g Dihydroxyaluminum Aminoacetate and 30g fluocinolone acetonide, high speed electric joins in the above-mentioned 3. liquid that is stirring after stirring and making it be agranular thin starchiness down.
5. above-mentioned 2. liquid is poured into and pour into above-mentioned 4. liquid again after froth in vacuum becomes the glue machine, start the back about 10min of running and can become glue.
6. this is had three-dimensional grid gel structure thing and move in the film-forming machine, configure non-woven fabrics egative film and airtight synthetic plastic top flat width, and behind the mesophase gel layer thickness, can start film-forming machine, promptly get and open multi-functional protecting greatly and hinder the subsides of three-dimensional grid gel dressing.
7. an above-mentioned 6. big dressing paste of opening, put into ventilating kitchen layer lattice one by one.Start big air quantity, make gel dehydration aging, can lift easily and till when not being stained with gel up to the dressing paste teleblem.
8. above-mentioned 7. the big dressing paste of opening, to put into film cutting machine and be cut into behind the various sizes dressing paste aluminium foil bag of can vacuum packet packing into, this is that multi-functional protecting hindered the three-dimensional grid gel dressing and pasted finished product.
Embodiment 6:
Preparation is protected and is hindered the subsides of three-dimensional grid gel dressing
1. claim propylene glycol 2500g, glycerol 1000g has used the dissolved 25g synthetic borneol of small amount of ethanol, and the 25g trichloro hydroxyl diphenyl ether stirs under the room temperature and makes homogeneous.
2. claim hydroxyethyl-cellulose 200g, poly propenoic acid sodium acrylate copolymer 300g, sodium polyacrylate 300g adds in the above-mentioned 1. liquid that is stirring successively, and it is molten entirely to make sure item by item.
3. measure distilled water 6000ml, add the 150g polyvinylpyrrolidone under the heated and stirred.Treat that it adds 95g sodium chloride after molten entirely again, the 150g diisopropanolamine (DIPA) stirs up to molten entirely.
4. measure distilled water 3000ml, add 200g bismuth aluminate and 50g methylprednisolone, high speed electric joins in the above-mentioned 3. liquid that is stirring after stirring and making it be agranular thin starchiness down.
5. above-mentioned 2. liquid is poured into and pour into above-mentioned 4. liquid again after froth in vacuum becomes the glue machine, start the back about 10min of running and can become glue.
6. this is had three-dimensional grid gel structure thing and move in the film-forming machine, configure non-woven fabrics egative film and airtight synthetic plastic top flat width, and behind the mesophase gel layer thickness, can start film-forming machine, promptly get and open multi-functional protecting greatly and hinder the subsides of three-dimensional grid gel dressing.
7. an above-mentioned 6. big dressing paste of opening, put into ventilating kitchen layer lattice one by one.Start big air quantity, make gel dehydration aging, can lift easily and till when not being stained with gel up to the dressing paste teleblem.
8. above-mentioned 7. the big dressing paste of opening, to put into film cutting machine and be cut into behind the various sizes dressing paste aluminium foil bag of can vacuum packet packing into, this is that multi-functional protecting hindered the three-dimensional grid gel dressing and pasted finished product.
Claims (10)
1, a kind of pharmaceutical composition that is used for healing skin wound is characterized in that component is as follows:
Aluminum hydroxyacetate 0.5～10 weight portion,
Propylene glycol 15～25 weight portions,
Glycerol 15-25 weight portion,
Hydroxyethyl-cellulose 1～4 weight portion,
Synthetic borneol 0.5～3 weight portion,
Sodium chloride 0.7～1.2 weight portion,
Hydrocortisone 0.2～1 weight portion and
Bromo geramine 0.05～0.2 weight portion.
2, the pharmaceutical composition that is used for healing skin wound according to claim 1 is characterized in that also available other of aluminum hydroxyacetate contains aluminide and replace, and comprises bismuth aluminate, Dihydroxyaluminum Aminoacetate, Basic Magnesium Aluminum Carbonate.
3, the pharmaceutical composition that is used for healing skin wound according to claim 1 is characterized in that propylene glycol also can be replaced by three pharmaceutically acceptable diol compound and derivants thereof more than the carbon atom, as butanediol.
4, the pharmaceutical composition that is used for healing skin wound according to claim 1 is characterized in that hydroxyethyl-cellulose, can be replaced by the cellulose derivative of other high pressure resistant sterilization.
5, the pharmaceutical composition that is used for healing skin wound according to claim 1, it is characterized in that hydrocortisone also can be replaced by other glucocorticoids that is used for the treatment of anaphylaxis dermatosis, dermatitis, eczema, skin and mucosa pruritus clinically, as dexamethasone acetate, cortisone, fludrocortisone, prednisone, triamcinolone, fluocinolone acetonide, betamethasone, methylprednisolone, prednisolone.
6, the pharmaceutical composition that is used for healing skin wound according to claim 1 is characterized in that bromo geramine also can be replaced by non-harmful antiseptic, as hibitane.
7, the pharmaceutical composition that is used for healing skin wound according to claim 1, it is characterized in that the combination of aluminum hydroxyacetate and hydrocortisone, can contain the combination replacement that aluminide comprises bismuth aluminate, Dihydroxyaluminum Aminoacetate, Basic Magnesium Aluminum Carbonate and other glucocorticoids such as dexamethasone acetate, cortisone, fludrocortisone, prednisone, triamcinolone, fluocinolone acetonide, betamethasone, methylprednisolone, prednisolone by other.
8, the pharmaceutical composition that is used for healing skin wound according to claim 1 is characterized in that aluminum hydroxyacetate: propylene glycol: the ratio of hydroxyethyl-cellulose combination is 1: 12.5: 1.
9, the pharmaceutical composition that is used for healing skin wound according to claim 1 is characterized in that its viscosity can be adjusted by the dosage of hydroxyethyl-cellulose and aluminum hydroxyacetate, thereby compositions is deployed into paste, pasty state, frost, emulsion dosage form.
10, the pharmaceutical composition that is used for healing skin wound according to claim 1, it is characterized in that to coat solid support surface or wherein, for example gauze, sthptic sponge, be combined into protect hinder gauze, protect hinder paste, protect hinder cotton, protect and hinder band, protect and hinder sponge, Wound protective film.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610052503 CN1919209A (en) | 2006-07-10 | 2006-07-10 | Pharmaceutical composition for healing skin wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610052503 CN1919209A (en) | 2006-07-10 | 2006-07-10 | Pharmaceutical composition for healing skin wound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1919209A true CN1919209A (en) | 2007-02-28 |
Family
ID=37777146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610052503 Pending CN1919209A (en) | 2006-07-10 | 2006-07-10 | Pharmaceutical composition for healing skin wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1919209A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764268A (en) * | 2011-03-18 | 2012-11-07 | 南京维赛医药科技有限公司 | Acid-base neutralization solution for protecting human body from being burned by chemical substances |
| CN106390093A (en) * | 2015-07-28 | 2017-02-15 | Zo皮肤健康公司 | Post-procedure skin care systems, compositions, and methods of use thereof |
| CN110368498A (en) * | 2019-08-26 | 2019-10-25 | 瑞希(重庆)生物科技有限公司 | A kind of preparation and preparation method thereof promoting wound healing |
| CN114431233A (en) * | 2022-01-25 | 2022-05-06 | 重庆华邦制药有限公司 | Composition for preparing disinfectant |
-
2006
- 2006-07-10 CN CN 200610052503 patent/CN1919209A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764268A (en) * | 2011-03-18 | 2012-11-07 | 南京维赛医药科技有限公司 | Acid-base neutralization solution for protecting human body from being burned by chemical substances |
| CN106390093A (en) * | 2015-07-28 | 2017-02-15 | Zo皮肤健康公司 | Post-procedure skin care systems, compositions, and methods of use thereof |
| CN106390093B (en) * | 2015-07-28 | 2019-04-05 | Zo皮肤健康公司 | Skin nursing system, composition and its application method after operation |
| CN110368498A (en) * | 2019-08-26 | 2019-10-25 | 瑞希(重庆)生物科技有限公司 | A kind of preparation and preparation method thereof promoting wound healing |
| CN114431233A (en) * | 2022-01-25 | 2022-05-06 | 重庆华邦制药有限公司 | Composition for preparing disinfectant |
| CN114431233B (en) * | 2022-01-25 | 2023-12-12 | 重庆华邦制药有限公司 | A composition for preparing disinfectant solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101982202B (en) | Medical hydrogel dressings and preparation method thereof | |
| US20200129654A1 (en) | Dressing Providing for the Controlled and Sustained Release of Metformin | |
| CN104257639B (en) | A kind of liniment for Wound treating and preparation method thereof | |
| CN104307032B (en) | A kind of pain relieving, antibacterial, stop blooding and promote the liquid dressing of wound healing | |
| CN103520767A (en) | Anti-microbial healing-promoting hydrogel dressing and preparation method therefor | |
| CN101773520B (en) | Compound antimicrobial containing polyvalent silver ions and preparation method thereof | |
| CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
| CN103083713A (en) | Sterile polymerized covering dressing for wound surface | |
| CN102784169A (en) | In situ gel preparation loaded with Kangfuxin and its preparation method and use | |
| CN108159024B (en) | Sustained-release patch for treating oral ulcer and preparation method thereof | |
| CN108635585A (en) | A kind of pharmaceutical composition for treating senile vahinitis and temperature sensitive slow-releasing gel used and preparation method | |
| CN103385926A (en) | Antibiosis gel for curing cervical and vaginal diseases of gynaecology | |
| CN106110369A (en) | A kind of medical composite type hyaluronic acid dressing and preparation method thereof | |
| WO2004110428A1 (en) | Anti-inflammatory analgesic adhesive patch | |
| CN107233617A (en) | A kind of wound dressing of liquid chitosan and its preparation and application | |
| CN108785739A (en) | A kind of full-service fluid adhesive bandage and preparation method thereof | |
| CN1919209A (en) | Pharmaceutical composition for healing skin wound | |
| RU2545735C1 (en) | Bioactive hydrogel wound coating | |
| US8889655B2 (en) | Compositions and methods for preventing infectious diseases in females | |
| RU2605343C1 (en) | Agent for treating pyoinflammatory processes in soft tissues and mucous membranes | |
| CN106466309A (en) | A kind of radiation-induced skin ulcer nursing emulsifiable paste and preparation method thereof | |
| CN113491788B (en) | Composition for digestive tract wound surface and digestive tract wound surface gel | |
| RU2601897C1 (en) | Agent for treating pyoinflammatory processes in soft tissues and mucous membranes | |
| CN102755414A (en) | Traditional Chinese medicine ointment for trauma wound and preparation method thereof | |
| RU2474422C1 (en) | Sorption plate formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070228 |